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Abstract 
Objectives and Design: Developing an effective HIV-1 vaccine that elicits broadly neutralizing 
HIV-1 human antibodies (bnAbs) remains a challenging goal. Extensive studies on HIV-1 have 
revealed various strategies employed by the virus to escape host immune surveillance. Here we 
investigated the human antibody gene repertoires of uninfected and HIV-1-infected subjects at 
genomic DNA (gDNA) and cDNA levels by deep sequencing followed by high-throughput 
sequence analysis to determine the frequencies of putative germline antibody genes of known 
HIV-1 monoclonal bnAbs (bnmAbs).  
Methods: Combinatorial gDNA and cDNA antibody libraries were constructed using the 
gDNAs and mRNAs isolated from uninfected and HIV-1-infected human PBMCs. All libraries 
were deep sequenced and sequences analyzed using IMGT/HighV-QUEST software 
(http://imgt.org/HighV-QUEST/index.action). The frequencies of putative germline antibodies of 
known bnmAbs in the gDNA and cDNA libraries were determined.   
Results and Conclusion: The human gDNA antibody libraries were more diverse in heavy and 
light chain V-gene lineage usage than the cDNA libraries, indicating that the human gDNA 
antibody gene repertoires may have more potential than the cDNA repertoires to develop HIV-1 
bnAbs. The frequencies of the heavy and kappa and lambda light chain variable regions (VHs 
and VKs/VLs) with identical V(D)J recombinations to known HIV-1 bnmAbs were extremely 
low in human antibody gene repertoires. However, we found relatively high frequencies of the 
VHs and VKs/VLs that used the same V-genes and had the same CDR3 length as known HIV-1 
bnmAbs regardless of (D)J-gene usage. B-cells bearing B-cell receptors of such VHs and 
VKs/VLs may be stimulated to induce HIV-1 bnAbs. 
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Introduction 
Since the discovery of HIV-1 in the early 1980’s, an effective HIV-1 vaccine that can elicit 
bnAbs has yet to be developed. Extensive studies on HIV-1 have revealed various mechanisms 
for viral escape from human immune surveillance, including genetic alterations, oligomerization 
of envelope (Env) glycoproteins, heavy glycosylation, and conformational masking [1-7]. But 
little is known about the potential of the human immune system to develop HIV-1 bnAbs. About 
10-30% HIV-1-infected subjects develop cross-clade neutralizing Abs in natural infection, but 
only 1-3% subjects develop high titers of potent bnAbs after years of chronic infection. 
Enormous efforts have been made to isolate bnmAbs from HIV-1-infected “elite controllers” 
whose sera exhibit high titers of broad neutralization activity. Four well-known bnmAbs, b12, 
2G12, 2F5 and 4E10, were identified more than a decade ago [8-11]. Many new and more potent 
bnmAbs were reported in the past three years, including PG9/16, HJ16, VRC01-03, VRC01-like 
Abs, PGTs and 10e8 [12-19]. Approximately twelve bnmAbs have been co-crystalized with Env 
and their neutralizing epitopes determined [18, 20-26]. However, immunogens designed to 
include the neutralizing determinants of several HIV-1 bnmAbs have not been successful in 
inducing the same or similar bnAbs.  
We and others have demonstrated that known HIV-1 bnmAbs had uncommon properties 
compared to bnmAbs against other microbes, including extensive somatic maturation and lack of 
measurable binding activity of their putative germline antibodies to Envs [13, 15, 16, 18, 27, 28], 
suggesting that HIV-1 infection or vaccination with HIV-1 Envs may not initiate the somatic 
maturation processes of the putative germline Abs to bnAbs. Deep sequencing of the cDNA-PCR 
products of memory B cells obtained from several “elite controllers” at different time points 
post-infection further revealed the limited use of heavy chain V-gene (IGHV) lineages for 
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developing HIV-1 bnAbs in a single infected subject [17, 18, 29]. The infrequency of developing 
bnAbs in natural infection, the uncommon properties of known HIV-1 bnmAbs, the confined 
usage of IGHV lineages for developing bnAbs in a single infected subject, and the failure in 
inducing the same or similar bnmAbs by vaccine immunogens prompted us to investigate the 
human antibody gene repertoire for the availability of the putative germline antibody genes of 
known HIV-1 bnmAbs at both genomic DNA (gDNA) and cDNA levels and the possibility for 
existence of alternative germline antibody genes that may potentially mature to HIV-1 bnAbs. 
The gDNAs of peripheral B cells in uninfected human subjects presumably possess the initial 
rearranged antibody gene repertoire for affinity maturation upon infection or vaccination. We 
hypothesized that antibody gene repertoire at the gDNA level may be more diverse than that at 
the cDNA level. Therefore, we developed a methodology for constructing large combinatorial 
gDNA antibody libraries and constructed one large nonimmune gDNA library using the PMBCs 
obtained from 300 uninfected healthy humans and three immune gDNA libraries using the 
PBMCs obtained from three HIV-1-infected “elite controllers”. Their corresponding cDNA 
libraries were simultaneously constructed. We compared the antibody gene repertoires of the 
four gDNA antibody libraries with those of the corresponding cDNA libraries by deep 
sequencing. Sequence analysis results suggest that the frequencies of the putative germline 
antibody genes of known HIV-1 bnmAbs were extremely low, but alternative germline antibody 
genes may be explored to elicit HIV-1 bnAbs. 
 
Materials and methods 
Preparation of human PBMCs 
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The PBMCs of healthy volunteers were obtained from The University of Hong Kong (Hong 
Kong, China). PBMCs from patient 1 (pt1) were obtained from Aaron Diamond AIDS Research 
Center, Rockefeller University (New York, USA). PBMCs from patient 2 and 3 (pt2 and pt3) 
were obtained from National Center for AIDS/STD Control and Prevention, China CDC (Beijing, 
China). All these experiments were approved by ethical committees of the respective institutes, 
and conducted according to local guidelines and regulations. All three patients were elite 
controllers. Pt1 was infected with clade B virus whose serum exhibited high titers of broadly 
neutralizing activity, and a panel of bnmAbs were isolated from pt1 PBMCs by single memory 
cell sorting using gp120 C-C core protein as a bait [pt1 in [18, 28]]. Pt2 and pt3 were infected 
with clade B’ virus and naive to antiretroviral therapy [30]. The sera of pt2 and pt3 also exhibited 
cross-clade neutralization activity (data not shown). Heparinized whole blood samples were used 
to isolate human PBMCs by Ficoll density gradient separation.  
 
Isolation of gDNA, total RNA and mRNA from human PBMCs 
Five to ten million PBMCs were collected from each 5 mL of heparinized whole blood and were 
used to isolate gDNA and total RNA using Allprep DNA/RNA Mini kits (Qiagen) following the 
protocol provided by the manufacturer. The gDNA was used as a template for amplification of 
heavy chain variable regions (VHs) and kappa and lambda light chain variable regions 
(VKs/VLs) by semi-nested PCR for construction of gDNA antibody single chain antibody 
fragment (scFv) libraries in phagemid vector pComb3X. Total RNA from uninfected individual 
PBMCs were pooled and mRNA was prepared from the pooled total RNA using the “Oligotex 
mRNA Mini Kit” (Qiagen). The mRNA was used to reverse transcribe cDNA for construction of 
cDNA antibody libraries. 
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Construction of gDNA antibody scFv libraries 
A total of 67 primers were designed and used in semi-nested PCR reactions to amplify VHs and 
VKs/VLs using gDNA as a template, and in SOE-PCR to assemble scFvs for gDNA scFv library 
construction (Table S1). Reverse primers were mixed at equal molar concentrations prior to 
semi-nested PCR. Each sense primer annealing to leader sequences or framework 1 (FR1) 
regions of VHs or VKs/VLs was paired with the corresponding mixed anti-sense primers and 
used at the same final concentration (10 μM) in the 1st or 2nd round of PCRs. Each 1st round of 
PCR was carried out in a reaction volume of 100 L containing 90 ng gDNA as a template by 
running the following PCR program: initial denaturing at 95℃ for 3 min, 10 cycles of 95℃ for 
15 sec, 45℃ for 30 sec, 72℃ for 45 sec, 20 cycles of 95℃ for 15 sec, 55℃ for 30 sec, 72℃ for 
45 sec, and an extension cycle of 72℃ for 10 min. The 2nd round of PCR was carried out using 
the corresponding 1
st
 round PCR product as a template and running the following PCR program: 
initial denaturing at 95℃ for 3 min, 30 cycles of 95℃ for 15 sec, 55℃ for 30 sec, 72℃ for 30 sec 
and an extension cycle of 72℃ for 10 min. Semi-nested PCR products were gel-purified using a 
QIAquick gel extraction kit (Qiagen). The purified VHs and VKs/VLs were then covalently 
linked by a flexible (G4S)3 linker by SOE-PCR to assemble scFvs using the primer pairs 
Sfi5new/LINKR and LINKF/Sfi3hisR. The SOE-PCR products were gel-extracted, digested with 
SfiI and ligated to pComb3X. The ligated products were then electroporated into TG1 
electrocompetent cells.  
 
Construction of cDNA antibody Fab libraries 
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The pooled mRNA from the healthy donors’ PBMCs and the mRNA from three elite controllers 
were used to reverse transcribe cDNA by using the “SuperScript III cDNA Synthesis Kit”. The 
cDNA was used as a template to amplify VHs and kappa/lambda light chains (LCs) by PCR 
using high-fidelity DNA polymerase and primers annealing to FR1s and FR4s of human 
antibody heavy chain variable regions and primers annealing to FR1s and constant regions of 
human antibody light chains (Table S2). The human antibody heavy chain first constant domain 
(CH1) sequence was then attached to the VHs by SOE-PCR to assemble Fds. LCs and Fds were 
further assembled by SOE-PCR to obtain Fab fragments. The Fab fragments were then ligated to 
pComb3X, and ligated products electroporated into TG1 electrocompetent cells.  
 
Deep sequencing and sequence analysis 
Primers annealing to pComb3X vector or heavy and light chain constant regions (Table S1 and 
S2) were used to amplify the scFvs from the gDNA antibody libraries and Fds and LCs from the 
cDNA antibody libraries. Gel-purified PCR products were sent for deep sequencing using the 
Roche 454 genome sequencer (GS) FLX. Trim sequences (≥ 290 nt) were analyzed using 
IMGT/HighV-QUEST software (http://imgt.org/HighV-QUEST/index.action).   
 
Results 
Construction of large combinatorial DNA and cDNA antibody libraries 
We prepared the gDNAs from the PBMCs of 300 uninfected healthy donors and amplified the 
VHs and VKs/VLs by semi-nested PCR using pooled gDNA as a template and a set of primers 
that annealed to the leader sequence or framework 1 (FR1) or FR4 of each VH or VK/VL family 
(Table S1). The VHs and VKs/VLs were then covalently linked by a flexible (G4S)3 linker by 
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strand overlap extension (SOE)-PCR to assemble scFvs. The resultant combinatorial gDNA scFv 
library, including two sub-libraries, designated NIgH/gK and NIgH/gL, in pComb3X contained 
over 600 million individual clones. Similarly, we constructed three immune gDNA scFv libraries 
using the gDNAs isolated from pt1, pt2 and pt3. Each immune gDNA scFv library had kappa 
and lambda sub-libraries except that pt1 lambda sub-library was omitted. Five sub-libraries were 
designated pt1gH/gK, pt2gH/gK, pt2gH/gL, pt3gH/gK and pt3gH/gL, and each sub-library 
contained 1-6 billion individual clones. We simultaneously constructed corresponding 
combinatorial cDNA antibody Fab libraries except that construction of a cDNA Fab library using 
pt1 PBMCs was omitted because the isolation of bnmAbs by single cell sorting of memory B-
cells from pt1 PBMCs has been reported [18, 28]. The resultant nonimmune and immune cDNA 
Fab kappa and lambda sub-libraries were designated NIH/NIK and NIH/NIL, pt2H/pt2K and 
pt2H/pt2L, and pt3H/pt3K and pt3H/pt3L, respectively. Each sub-library contained 1-6 billion 
individual clones.  
 
More diverse IGHV lineage usage in the gDNA libraries than in the cDNA libraries 
We amplified the scFvs from the gDNA libraries and the Fds and LCs from the cDNA libraries 
using primers that annealed to the pComb3X vector or to the constant regions of heavy or light 
chains (CH1 and CL, respectively) (Table S1 and S2) and sent the PCR products for deep 
sequencing. We obtained trim sequences (>290nt) from each library ranging from 23,530 to 
88,331 for VHs, and from 17,285 to 28,110 for VKs and from 21,480 to 30,199 for VLs. 
Sequence analysis showed different patterns of using various IGHV and IGKV/IGLV (kappa and 
lambda light chain V-genes) lineages in different gDNA and cDNA libraries, and the differences 
between the gDNA and corresponding cDNA libraries were more significant than those between 
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the nonimmune and immune gDNA or cDNA libraries (Fig. 1-3). The gDNA libraries were more 
diverse overall than the cDNA libraries in using various IGHV lineages (Fig. 1 and 2). Among 
the four gDNA heavy chain libraries, NIgH and pt1gH showed a similar pattern of various IGHV 
lineage usage, while pt2gH and pt3gH were significantly different from NIgH and pt1gH in 
using IGHV1, 2 and 6 lineages (Fig. 1 and 2). Compared to the gDNA heavy chain libraries, the 
corresponding cDNA heavy chain libraries had significantly higher percentages of clones using 
IGHV1 and IGHV3 lineages (Fig. 1), and were biased to certain VH1 and VH3 subfamilies, 
including IGHV1-18, 1-2 and 1-69, and IGHV 3-11, 3-21, 3-23, 3-30, 3-33, 3-49, 3-7 and 3-74 
(Fig. 2). The patterns of various IGKV/IGLV lineage usages in the nonimmune and immune 
gDNA libraries were similar except for pt1gK library (Fig. 1 and 3). The nonimmune and 
immune cDNA libraries also showed a similar pattern in using various IGKV/IGLV lineages. 
Both nonimmune and immune cDNA antibody libraries heavily used IGKV3 and IGLV1 
lineages (Fig. 1 and 3). These results indicate that HIV-1 infection shapes the patterns of various 
IGHV lineage usages, but the caused changes at the cDNA level are much less significant 
compared to the changes at the gDNA level. The differences between the gDNA and cDNA 
antibody gene repertoires in HIV-1 uninfected (nonimmune) humans reflect host immune 
regulations, and such regulations may largely determine the host-dependent immune response to 
HIV-1 infection. 
 
Extremely low frequency of the VHs and VKs/VLs with identical V(D)J recombinations to known 
HIV-1 bnmAbs 
To investigate the potential of basal human antibody gene repertoires to develop HIV-1 bnAbs, 
we analyzed the trim VH sequences and counted the number of VHs that had identical putative 
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VDJ recombinations to five known CD4bs bnmAbs b12, VRC01, VRC03, NIH45-46 and 
3BNC60, and two glycan- and loop-specific bnmAbs PG9 and pGT127. To our surprise, we 
found that the frequencies of the VHs with identical putative VDJ recombinations to these 
known HIV-1 bnmAbs in both nonimmune and immune gDNA and cDNA libraries were 
extremely low (Table 1). We did not find any VHs that had identical VDJ recombinations 
compared to the known bnmAbs in the nonimmune and three immune gDNA libraries (Table 1). 
We found a total of 5, 10 and 2 productive VHs (with in-frame junctions) in the cDNA libraries 
with exactly the same putative VDJ recombinations as VRC01, VRC03 and NIH45-46, 
respectively (Table 1). However, their junction regions and the length of the HCDR3s were very 
different compared to the respective bnmAbs (data not shown), suggesting the unlikelihood for 
them to mature to VRC01-like bnAbs. We did a similar search for VHs that had identical VDJ 
recombinations to a non-neutralizing or weakly neutralizing CD4-induced (CD4i) mAb X5 and a 
bnmAb against SARS-CoV, m396 [31, 32]. We found 4 productive VHs in two immune gDNA 
libraries (1 in pt2gH and 3 in pt3gH) and a total of 28 productive VHs in the cDNA libraries (12 
in NIH, 2 in pt2H, and 14 in pt3H) that had identical putative VDJ recombinations to X5, but all 
these VHs had a shorter HCDR3 than that of X5 (24 amino acids, AA). We found 1 VH in pt1gH 
library and 1 VH in NIH library that had exactly the same putative VDJ recombination as m396, 
but none of them had the same HCDR3 length as that of m396 (11AA). These results indicate 
that the chance of having a VH with a defined VDJ recombination along with a specific HCDR3 
length could be extremely low in human antibody gene repertoires. 
The frequencies of the VKs that had the identical VJ recombinations to the known HIV-1 
bnmAbs in both nonimmune and immune gDNA and cDNA libraries were also very low except 
that the frequencies of the VKs with the identical VJ recombination to b12 VK (IGKV3-20 / 
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IGKJ2) were relatively high (Table 1). X5 used the same VJ recombination as b12, so the 
frequencies of the VKs with identical VJ recombination to X5 were also relatively high. 
Interestingly, we found that the frequencies of the VLs with the identical VJ recombinations to 
bnmAbs PG9 and PGT127 were also relatively high, while the frequencies of the VLs with the 
identical VJ recombination to m396 were very low (Table 1).   
 
Relatively high frequencies of VHs and VKs/VLs that used the same or very similar IGHVs and 
IGKVs/IGLVs and had the same length of CDR3s as known HIV-1 bnmAbs regardless of (D)J-
gene usage 
It is usually difficult to determine which D- and J-genes were recombined with the V-genes to 
generate VHs, owing to the complexity of VDJ recombination events. Therefore, we searched for 
productive VHs that used the same or very similar IGHVs and had the same length of HCDR3 as 
known HIV-1 bnmAbs regardless of D- and J-gene usage. The frequencies of such VHs were 
relatively high in the nonimmune and immune gDNA and cDNA libraries compared to the 
frequencies of the VHs with exactly the same VDJ recombinations of known HIV-1 bnmAbs 
except for VRC03, PG9 and PGT127 that had long HCDR3s (23, 30 and 25 AA, respectively) 
(Table 2). X5 also had a long HCDR3 (24 AA), so the frequencies of the VHs that used the same 
or very similar IGHV of X5 and had the same HCDR3 length were not higher than the 
frequencies of the VHs with exactly the same VDJ recombinations of X5. Similar analysis of 
trim VKs/VLs also showed relatively high frequencies of the VKs/VLs that used the same or 
very similar IGKVs/IGLVs and had the same length of CDR3 as known HIV-1 bnmAbs 
regardless of J-gene usage, especially for b12, PG9 and PGT127 (Table 2). 
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Discussion 
B-cell antigen receptors (BCRs) develop as B-cells differentiate. VDJ recombination for the 
heavy chain and VJ recombination for the light chain occur sequentially at pro-B and pre-B 
stages, respectively, in the bone marrow. Immature B-cells exit the bone marrow and enter the 
peripheral system where new emigrant B cells differentiate into immature then mature naïve B-
cells. Mature B-cells undergo somatic maturation upon immunogen stimulation and differentiate 
into Ab-secreting plasma cells or memory B-cells. Thus, the peripheral blood contains a 
population of B-cells that have undergone V(D)J recombinations, and the gDNAs of peripheral 
B-cells of nonimmune human subjects possess the basal rearranged antibody gene repertoire for 
antibody affinity maturation. The genome-based antibody gene repertoire may differ from the 
cDNA-based antibody gene repertoire owing to the different transcriptional and / or translational 
levels of different antibody genes, and both repertoires may be shaped upon viral infection or 
vaccination. Therefore, we constructed a large combinatorial nonimmune and three immune 
human gDNA antibody libraries and their corresponding cDNA antibody libraries for 
comparison of antibody gene repertoires at the gDNA and cDNA levels by deep sequencing and 
for subsequent isolation of Env-specific germline or intermediate antibodies (with low level of 
somatic maturation) by phage display. We found that frequencies of the VHs and VKs/VLs with 
identical putative V(D)J recombinations to known HIV-1 bnmAbs were extremely low in both 
nonimmune gDNA and cDNA libraries, suggesting that known HIV-1 bnmAbs may not be 
derived from the putative germline antibodies, or the chance for such direct maturation may be 
very low. If a certain combination of putative germline heavy and light chains is required for 
HIV-1 bnAbs, the frequency of such germline antibody genes may be even lower. Compared to 
the lack of measurable binding of putative germline antibodies of known HIV-1 bnmAbs to Env 
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and the requirement of extensive somatic maturation for broadly neutralizing activity [13, 27], 
limited availability of B-cells bearing proper germline antibody genes that may mature to HIV-1 
bnAbs upon stimulation may be a formidable challenge for developing an effective HIV-1 
vaccine. The extremely low frequency of the putative germline antibody genes of known HIV-1 
bnmAbs in the human antibody gene repertoires suggests that the approach for eliciting HIV-1 
bnAbs by identifying primary immunogens to trigger the putative germline antibodies of known 
HIV-1 bnmAbs in vivo may have a very limited chance of success. However, our further 
sequence analyses revealed relatively high frequencies of the VHs and VKs/VLs in the human 
antibody gene repertoires that use the same or very similar IGHVs and IGKVs/IGLVs and have 
the same CDR3 length as known HIV-1 bnmAbs regardless of (D)J-gene usage. B-cells 
harboring such VHs and VKs/VLs may be stimulated to induce bnAbs. Note that we used the 
plasmids from the cDNA Fab libraries and the gDNA scFv libraries as templates for PCR 
amplification of the VHs and VKs/VLs for deep sequencing. The cDNA Fab libraries were 
constructed earlier and used in our previous studies. We did not convert the Fab libraries to scFv 
libraries because it was not necessary to do so. Conversion between two different formats of 
antibody libraries may cause loss of antibody diversity and result in bias to certain antibody gene 
families. 
Exploring the human gDNA antibody gene repertoire may be another approach for eliciting 
HIV-1 bnAbs. As we hypothesized, the gDNA antibody gene repertoires showed more diverse 
usages of IGHV lineages than the cDNA repertoires. Indeed, we have isolated a panel of RSC3-
specific antibodies from our combinatorial gDNA libraries, but not from the cDNA libraries 
(manuscript in preparation). The isolated RSC3-specific antibodies had no or very low levels of 
somatic maturation and used diverse V(D)J recombinations, but they competed with mature b12 
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and VRC01 for binding to engineered Env, RSC3 [13], suggesting their potential to mature to 
VRC01-like bnAbs. We are currently doing in vitro maturation and selection to confirm that they 
can potentially mature to VRC01-like bnAbs.  
We obtained 33,436 and 80,331 trim VH sequences from 454 deep sequences of the nonimmune 
gDNA and cDNA libraries, respectively (Table 1 and 2), which were comparable to the 
theoretical maximum diversity of the basal human VH gene repertoire (3.1x10
4
). The unequal 
usage of IGHV, IGHD and IGHJ genes in the nonimmune gDNA library suggests that VDJ 
recombination may not be a random event. The differences may be amplified by host immune 
regulations to remove or functionally silence B-cells expressing autoimmune antibodies or to 
deplete the B-cells that recognize B-cell superantigens [33-35]. This could lead to a different 
frequency of various germline antibody genes in the initial antibody gene repertoire for affinity 
maturation. For example, the VHs using IGHV1-2 or with HCDR3s of long length (20 AA and 
over) were significantly less frequent than the VHs using IGHV1-46 or with HCDR3s of 
medium length (10-15 AA) (Fig. 2 and data not shown). Arnaout et al. also showed that V, D, 
and J segments were utilized with different frequencies, resulting in a highly skewed 
representation of VDJ combinations in the human antibody gene repertoire [36]. However, they 
found that the pattern of segment usage was almost identical between two different individuals. 
Our result seems different from their finding. We found that IGHV lineage usage differs from 
individual to individual. In addition, they reported that IGHV1-2 lineage accounted for 2-3% 
sequence in non-immune human antibody gene repertoire [36]. We found a similar percentage in 
our cDNA libraries, but the percentages of IGHV1-2 lineage in gDNA libraries were 10-100-fold 
lower (Fig. 2). The more diverse usages of IGHV lineages may account for this phenomenon.  
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Our study suggests the potential of the human immune system to develop HIV-1 bnAbs, which 
may have implications for vaccine development. In addition to searching for proper germline 
antibodies as targets for vaccine immunogen design, immune modulations may be required to 
tackle possible obstacles posed by the host and/or the virus to affinity maturation to HIV-1 
bnAbs.      
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Figure legend 
Fig. 1 Percentage of VH and VK/VL family in nonimmune and immune gDNA and cDNA 
antibody libraries. NIgH/K/L: nonimmune gDNA scFv library; NIH/K/L: nonimmune cDNA 
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Fab library; pt1-3gH/K/L: patient gDNA scFv library; pt1-3H/K/L: patient cDNA Fab library. 
Note: pt1gL library is not available.  
Fig. 2 Percentage of IGHV lineages in the nonimmune and immune gDNA and cDNA 
libraries. NIgH: nonimmune gDNA scFv library; NIH: nonimmune cDNA Fab library; pt1-3gH: 
patient gDNA scFv library; pt1-3H: patient cDNA Fab library.  
Fig. 3 Percentage of IGKV/IGLV lineages in the nonimmune and immune gDNA and 
cDNA libraries. NIgK/L: nonimmune gDNA scFv library; NIK/L: nonimmune cDNA Fab 
library; pt1-3gK/L: patient gDNA scFv library; pt1-3K/L: patient cDNA Fab library. 
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 Fig. 1 Percentage of VH and VK/VL family in nonimmune and immune gDNA and cDNA 
antibody libraries. NIgH/K/L: nonimmune gDNA scFv library; NIH/K/L: nonimmune cDNA 
Fab library; pt1-3gH/K/L: patient gDNA scFv library; pt1-3H/K/L: patient cDNA Fab library. 
Note: pt1gL library is not available.  
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Figure
 Fig. 2 Percentage of IGHV lineages in the nonimmune and immune gDNA and cDNA 
libraries. NIgH: nonimmune gDNA scFv library; NIH: nonimmune cDNA Fab library; pt1-3gH: 
patient gDNA scFv library; pt1-3H: patient cDNA Fab library.  
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Fig. 3 Percentage of IGKV/IGLV lineages in the nonimmune and immune gDNA and 
cDNA libraries. NIgK/L: nonimmune gDNA scFv library; NIK/L: nonimmune cDNA Fab 
library; pt1-3gK/L: patient gDNA scFv library; pt1-3K/L: patient cDNA Fab library. 
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Table 1 Number of productive VHs and VKs/VLs with identical putative V(D)J 
recombinations to known HIV-1 bnmAbs. CD4i mAb X5 and bnmAb m396 against SARS-
CoV were included for comparison.  
BnmAbs 
VHs 
IGHV IGHD IGHJ NIgH pt1gH pt2gH pt3gH NIH pt2H pt3H 
b12 HV1-3*01 HD2-21*01 F  HJ6*03 F 0 0 0 0 0 0 0 
VRC01 HV1-2*02 HD2-21*01 HJ2*01  0 0 0 0 4 0 1 
VRC03 HV1-2*02,04; HV1-8*01 HD2-21*01 HJ2*01 0 0 0 0 6 0 4 
NIH45-
46 
HV1-2*02 HD1-26 HJ2*01 0 0 0 0 1 0 1 
3BNC60 HV1-2*01 HD3-3 HJ2*01 0 0 0 0 0 0 0 
PG9 HV3-33*05 HD1-1*01 F HJ6*03 F 0 0 0 0 0 0 0 
PGT127 HV4-61*05 HD3-16*02 HJ5*02 0 0 0 0 0 0 0 
X5 HV1-69*01 HD3-22*01 HJ4*02 F 0 0 1 3 12 2 14 
m396 HV1-69*05 HD5-18*01 HJ6*02 F 0 1 0 0 1 0 0 
Total no. of trim VH sequences 
33,436 23,530 44,027 42,160 80,331 74,053 77,176 
BnmAbs 
VKs/VLs 
IGKV / IGLV   IGKJ / IGLJ NIgK/L pt1gK pt2gK/L pt3gK/L NIK/L pt2K/L pt3K/L 
b12 IGKV3-20 
 
IGKJ2 136 3 179 124 1,172 1,093 1,280 
VRC01 IGKV3D-15 IGKJ2 0 0 0 0 0 0 0 
VRC03 IGKV3-NL5 IGKJ2 0 0 0 0 1 5 0 
NIH45-
46 
IGKV3D-15 IGKJ2 0 0 0 0 0 1 0 
3BNC60 IGKV1-33, IGKV1D-33 IGKJ3 0 0 1 0 1 2 0 
PG9 IGLV2-14 IGLJ3 181 NA 100 167 381 605 195 
PGT127 IGLV2-8 IGLJ2, IGLJ3 90 NA 13 114 483 255 102 
X5 IGKV3-20 IGKJ2 136 4 179 124 1,172 1,093 1,280 
m396 IGLV3-21 IGLJ1 0 NA 0 0 5 28 19 
Total no. of trim VK and VL sequences  23,670 21,254 19,162 17,285 26,902 26,508 27,639 
 
 
  
Table
Table 2 Number of VHs and VKs/VLs that used the same or very similar V-genes and had 
the same CDR3 length as known HIV-1 bnmAbs. CD4i mAb X5 and bnmAb m396 against 
SARS-CoV were included for comparison.  
BnmAbs 
VHs 
IGHVs CDR3 length  NIgH pt1gH pt2gH pt3gH NIH pt2H pt3H 
b12 HV1-3*01,02;1-8*02;1-18*01,03 20 AA 3 10 0 0 34 69 58 
VRC01 HV1-2 *01-05 14 AA 1 2 0 1 79 122 210 
VRC03  HV1-2*02,04,05;1-8*01,02 23 AA 0 2 0 0 8 4 58 
NIH45-46 HV1-2*02-05;1-3*01 18 AA 10 17 10 1 47 48 115 
3BNC60 HV1-2*01-05 17 AA 0 7 0 0 37 24 227 
PG9 HV3-33*01,05,06; &3-30*02,03 30 AA 0 0 0 0 0 0 0 
PGT127 HV4-39*03,06,07;4-61*05;4-b*02 25 AA 0 1 0 0 1 2 0 
X5 HV1-69*01,05,06,12,13 24 AA 2 3 0 2 3 3 4 
m396 HV1-69*01,02,04,05,09 11 AA 5 18 2 7 77 42 38 
Total no. of trim VH sequences 33,436 23,530 44,027 42,160 80,331 74,053 77,176 
BnmAbs 
VKs/VLs 
IGKVs / IGLVs CDR3 length  NIgK/L pt1gK pt2gK/L pt3gK/L NIK/L pt2K/L pt3K/L 
b12 IGKV3-20, 3D-20, 3-NL5, 3D-15 9 AA 177 5 218 159 1,834 1,665 2,117 
VRC01 IGKV3-15, 3D-15, 3-7 7 AA 1 0 0 1 0 0 1 
VRC03 IGKV3-NL5, 3-20, 3D-20, 3D-15 5 AA 1 0 5 0 7 10 6 
NIH45-46 IGKV3-15, 3D-15, 3-7 5 AA 0 0 1 1 1 4 0 
3BNC60 IGKV1-33, 1D-33, 1-39, 1D-39 5 AA 0 14 1 0 1 5 0 
PG9 IGLV2-14, 2-23 10 AA 377 
NA 
266 320 675 1,201 298 
PGT127 IGLV2-8, IGLV2-11 10 AA 143 26 179 522 343 142 
X5 KV3-20, KV3D-20, KV3-NL5, KV3D-7 9 AA 181 5 218 155 1,805 1,655 2,103 
m396 IGLV3-21, IGLV3-9 10 AA 9 NA 0 0 61 141 230 
Total no. of trim VK and VL sequences  23,670 21,254 19,162 17,285 26,902 26,508 27,639 
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